Berlin – In a significant development for the home health and hospice care sector, Kinderhook Industries, a middle-market private equity firm, has reached an agreement to acquire Enhabit Inc. (NYSE: EHAB) for approximately $1.1 billion in an all-cash transaction. The deal, announced Monday, February 23, 2026, will capture the publicly traded Enhabit private, removing its shares from trading upon the completion of the acquisition. This move reflects a broader trend of private equity investment in the healthcare industry, particularly in companies providing essential services to an aging population.
The acquisition is poised to reshape the landscape of home-based care, a sector experiencing substantial growth driven by demographic shifts and a preference for receiving medical services in the comfort of one’s own home. Enhabit, operating across 34 states, provides a vital service to patients and families, offering skilled nursing, rehabilitation, and palliative care. The deal aims to provide Enhabit with the financial backing and strategic guidance needed to further expand its reach and enhance the quality of its care, according to statements from both companies. The transaction is expected to close in the second quarter of 2026, pending regulatory approvals and customary closing conditions.
Barb Jacobsmeyer, president and CEO of Enhabit, emphasized the positive implications of the deal for all stakeholders. “Over the last four years, Enhabit has strengthened its role as a leading national provider of home health and hospice care, and this agreement is a terrific outcome for our stockholders, clinicians, caregivers, patients and their families,” she stated. Jacobsmeyer also highlighted that Kinderhook’s ownership will facilitate long-term investments in Enhabit’s workforce, clinical excellence, and innovation, free from the pressures of short-term public market expectations. This suggests a shift in focus towards sustainable growth and improved patient outcomes, rather than quarterly earnings reports.
Financial Details and Stockholder Benefits
Enhabit stockholders are set to receive $13.80 in cash for each share owned, representing a substantial premium over recent trading prices. According to the agreement, this price reflects a 24.4% premium compared to Enhabit’s closing stock price on February 20, 2026 – the last full trading day before the announcement – and a 33.8% premium over the company’s 60-day volume-weighted average share price as of the same date. Home Health Care News reported on the updated details of the acquisition.
Jeffrey Bolton, chairman of Enhabit’s board of directors, affirmed the board’s confidence in the transaction, stating that a thorough evaluation of the company’s business, outlook, and available opportunities led to the conclusion that the deal maximizes stockholder value. This assessment underscores the board’s fiduciary duty to act in the best interests of its shareholders, ensuring a favorable return on their investment. The financial terms of the deal signal a strong vote of confidence in Enhabit’s future prospects and its position within the rapidly evolving healthcare landscape.
Kinderhook Industries and its Healthcare Portfolio
Kinderhook Industries, the acquiring firm, is a well-established middle-market private equity firm with a strong track record of successful investments. The firm has raised over $10 billion in committed capital and focuses on businesses with “defensible niche market positioning,” suggesting a strategic approach to identifying and supporting companies with sustainable competitive advantages. Hospice News detailed Kinderhook’s strategy in this acquisition.
Kinderhook’s existing healthcare portfolio includes several prominent companies, including Better Health Group, a value-based primary care physician company; Avita Care Solutions, a healthcare and pharmacy provider; and AbsoluteCare, a value-based integrated healthcare provider. This demonstrates Kinderhook’s commitment to the healthcare sector and its expertise in identifying and nurturing companies that deliver high-quality, cost-effective care. The firm’s investment philosophy centers on providing operational support and strategic guidance to help its portfolio companies achieve their full potential.
Matt Bubis, managing director at Kinderhook, articulated the firm’s vision for Enhabit, emphasizing a commitment to supporting the company’s existing strengths and fostering its continued growth. “Thanks to its exceptional care teams and strong leadership, Enhabit has built a reputation for excellence across the health care industry,” Bubis said. “As a supportive partner, our role is to grow and foster the great operate they’re already doing and to help remove barriers so their teams can stay focused on patients. For us, this investment is simple – it’s about backing a great organization and giving it the room and resources to succeed for the long run.”
Enhabit’s Operations and Future Outlook
Headquartered in Dallas, Texas, Enhabit operates 249 home health locations and 117 hospice locations across 34 states, providing a broad geographic reach and serving a diverse patient population. The company’s extensive network of care providers delivers a range of services, including skilled nursing, physical therapy, occupational therapy, speech-language pathology, and hospice care. Enhabit’s commitment to providing compassionate, patient-centered care has established it as a trusted provider in the communities it serves.
Following the completion of the acquisition, Enhabit will retain its name and brand, signaling Kinderhook’s intention to preserve the company’s established identity and reputation. This continuity is expected to minimize disruption for patients, families, and employees, ensuring a smooth transition under recent ownership. The preservation of the Enhabit brand reflects Kinderhook’s recognition of the value of the company’s existing brand equity and its commitment to maintaining the high standards of care that Enhabit is known for.
The timing of this acquisition coincides with a planned leadership transition at Enhabit. Barb Jacobsmeyer, the current CEO, previously announced her intention to step down in July 2026, or upon the appointment of her successor. This transition will occur alongside the change in ownership, presenting both challenges and opportunities for the company as it navigates a new chapter under Kinderhook’s leadership. The appointment of a new CEO will be crucial in shaping Enhabit’s future direction and ensuring its continued success.
The Growing Demand for Home-Based Care
The acquisition of Enhabit by Kinderhook Industries underscores the increasing demand for home-based healthcare services. Several factors are driving this trend, including the aging of the baby boomer generation, the rising prevalence of chronic diseases, and a growing preference among patients for receiving care in the comfort of their own homes. Home health and hospice care offer a cost-effective alternative to traditional hospital-based care, reducing healthcare costs and improving patient outcomes. The COVID-19 pandemic further accelerated the adoption of home-based care, as healthcare systems sought to reduce the burden on hospitals and minimize the risk of infection.
The home healthcare market is projected to continue its robust growth trajectory in the coming years. According to a report by Grand View Research, the global home healthcare market size was valued at USD 303.1 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2030. Grand View Research projects the market to reach USD 564.9 billion by 2030. This growth is fueled by technological advancements, such as telehealth and remote patient monitoring, which enable healthcare providers to deliver care more efficiently and effectively.
The increasing demand for home-based care presents both opportunities and challenges for healthcare providers. To meet this demand, providers must invest in technology, expand their workforce, and improve their care coordination capabilities. Private equity firms, such as Kinderhook Industries, are playing an increasingly important role in financing these investments and supporting the growth of the home healthcare industry. The acquisition of Enhabit is a testament to the attractiveness of this sector and the potential for continued growth and innovation.
The next key milestone will be the completion of the acquisition in the second quarter of 2026, following regulatory approvals and customary closing conditions. Investors and industry observers will be closely watching how Kinderhook integrates Enhabit into its portfolio and executes its strategic plan for the company. We encourage readers to share their thoughts and perspectives on this significant development in the home healthcare sector in the comments below.
Worth a look